Safety and Efficacy of Ramipril in the Treatment of Essential Hypertension

Pacific Pharmaceuticals86 enrolled

Overview

The purpose of this study is to assess which drug is more effective of Ramiprin®(ramipril) and Tritace®(ramipril) in the Treatment of Essential Hypertension

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Essential Hypertension

Interventions

RamiprilDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * mild and moderate essential hypertension (90mmHg≤DBP≤110mmHg) Exclusion Criteria: * 180mmHg≤SBP * If differences greater than 20mmHg for SBP and 10mmHg for DBP between both arms are present on 3 consecutive readings * If differences greater than 20mmHg for SBP and 10mmHg for DBP are present on 3 consecutive readings * impaired hepatic function * imapaired renal function * angioedema * aortic valvular stenosis or obstrcutive ejection disorder * primary hyperaldosteronism * renal transplantation, bilateral renal artery stenosis or unilateral stenosis in a single kidney, hemodialysis * severe respiratory disease * congestive heart failure( New York Association functional class Ⅲ or Ⅳ) * malignant hypertension * labile angina pectoris or myocardial infarction in the last 3 months before study entry

Locations (1)

Seoul National University Hospital

Seoul, 28 Yeongeon-dong, Jongno-gu, South Korea

Outcomes

Primary Outcomes

Reduction of DBP(diastolic blood pressure)

Secondary Outcomes

Reduction of SBP(systolic blood pressure)

Percentage of patients with Dcrease of BP(blood pressure)

Percentage of patients with a Normalization of BP(blood pressure)

Artery stiffness(chang of pulse wave velocity)

Left ventricular diastolic function

Change of BNP

Change of CRP

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.